Home >  Pulmonology MDTV >  Pulmonology Shorts >  Journal Club- Guideline...

Journal Club- Guideline led COPD Management: Vilanterol or formoterol?

Written By :  Dr. Garima Soni
Written By :  Dr. Nandita Mohan
Published On 2025-03-31 03:00 GMT   |   Update On 2025-03-31 06:43 GMT
Advertisement
This review has been published in the Annals of the National Academy of Medical Sciences published by Scientific Scholar.
This comprehensive review evaluates the comparative efficacy, safety, and clinical advantages of vilanterol versus formoterol in the management of obstructive airway diseases, with a specific focus on the latest Global Initiative for Asthma (GINA) 2024 and Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 guideline recommendations.
Advertisement
Vilanterol, a novel long-acting β2-agonist (LABA), 24-hour duration of action, once-daily dosing when compared to formoterol’s twice-daily requirement.
Clinical trials in both asthma and chronic obstructive pulmonary disease (COPD) have shown vilanterol-containing combinations to be at least as effective as formoterol-based treatments in improving lung function, symptom control, and quality of life.
However, the GINA 2024 guidelines emphasize formoterol’s role in as-needed and maintenance and reliever therapy (MART) approaches for asthma management.
In COPD, Vilanterol aligns well with GOLD 2024 recommendations, particularly in fixed-dose combinations. Safety analyses indicate a favorable profile for vilanterol, even in high-risk populations. The once-daily dosing of vilanterol offers potential improvements in patient adherence and satisfaction, especially relevant in COPD management.
While direct cost comparisons are limited, improved clinical outcomes suggest potential cost-effectiveness benefits.
This review concludes that while vilanterol presents several advantages, particularly in COPD management and once-daily regimens, the choice between vilanterol and formoterol should be individualized based on patient characteristics, disease features, and current guideline recommendations.
Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Garima Soni

Dr. Garima Soni holds a BDS (Bachelor of Dental Surgery) from Government Dental College, Raipur, Chhattisgarh, and an MDS (Master of Dental Surgery) specializing in Orthodontics and Dentofacial Orthopedics from Maitri College of Dentistry and Research Centre. At medical dialogues she focuses on dental news and dental and medical fact checks against medical/dental mis/disinformation

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Managing Nasal Congestion in Allergic Rhinitis: Whats the Mechanism of Action of Allegra D ?

WHO Leads Global Call to Include Pregnant, Lactating Women in TB Research

COVID-19 Linked to Higher Risk of Asthma and Sinusitis: Study Finds

PCV20 Launch in India: A Single Dose, Science-Driven Approach for Pneumococcal Disease Control

Study Reveals Social Factors that May Triple the Risk of Long Covid

Maternal RSV Vaccine Cuts Infant Hospitalizations by 72 Percent: Study Finds

Micro labs to offer mucolytic solution for respiratory care with its recently launched Pulmucus range

Why Asthma Often Comes Back After Stopping Biologic Drugs? Study Sheds Light